Fevertree Drinks AI Stock Analysis
Want to see GB:FEVR full AI Analyst Report?
Fevertree Drinks (FEVR) AI Stock Analysis
Fevertree Drinks
(LSE:FEVR)
The score is driven primarily by solid underlying financial resilience (notably the very strong, low-leverage balance sheet) and a very constructive earnings-call outlook pointing to accelerating U.S. growth and meaningful medium-term profit uplift. Offsetting these positives are weak current technical momentum and a high P/E that leaves less room for near-term execution risk, especially given recent margin compression and cash-flow volatility.
Fevertree Drinks (FEVR) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- GBP 1.39B
- Dividend Yield
- 1.80%
- Average Volume (3M)
- 477.46K
- Price to Earnings (P/E)
- 45.0
- Beta (1Y)
- 1.14
- Revenue Growth
- 1.74%
- EPS Growth
- 2.83%
- Country
- UK
- Employees
- 285
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Beverages - Non-Alcoholic
Fevertree Drinks Business Overview & Revenue Model
Company Description
Fevertree Drinks Plc, together with its subsidiaries, specializes in crafting and distributing premium mixer beverages across the United Kingdom, the United States, Europe, and other international markets. Its diverse product portfolio includes popul...
How the Company Makes Money
Fever-Tree makes money primarily by selling branded premium mixers (e.g., tonic water, ginger beer, soda water and other carbonated mixers) to customers in different channels and geographies. Revenue is generated from the invoiced sale of finished go...
Fevertree Drinks Earnings Call Summary
The call was strongly positive. Management reported broad-based first-half growth, improving margins and EPS, accelerating U.S. momentum, successful diversification, strong cash generation, and confidence in a circa 60% EBITDA uplift over the next two years. The main challenges were the expected short-term U.S. margin impact from elevated marketing investment, the GBP 2.6 million EPR provision, U.K. on-trade challenges, European revenue phasing, and delayed working-capital benefits from U.S. onshoring.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For FY 2026, Fever-Tree expects U.S. revenue growth to accelerate as the year progresses, the rest of the group to deliver good underlying growth, reported revenue in Europe to be impacted as phasing benefits from the first half of the year unwind, and EBITDA to be in line with expectations; U.S. tariff refunds received in the second half will offset the full-year impact of the incremental GBP 2.6 million EPR provision, working capital will be similar year-on-year and significantly below historic levels, and the company remains confident of delivering high teens, 20% growth in the U.S. next year, with U.S. and group profitability expected to see a step change in 2027 and 2028, supporting consensus expectations of the circa 60% uplift in EBITDA over the next two years and at least GBP 100 million of free cash flow across 2027 and 2028; group EBITDA margin is expected to move from about 12.5% this year to high 14%-15%.
Fevertree Drinks Financial Statement Overview
Summary
Balance sheet strength (very low leverage; debt-to-equity ~0.02) supports resilience, but operating trends are mixed: revenue declined in 2025 (~-4.4%) and margins are well below 2020–2021 peaks. Cash flow is positive but inconsistent, including a weak 2023 and a sharp free-cash-flow decline in 2025.
Income Statement
62PositiveBalance Sheet
88Very PositiveCash Flow
55Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 345.80M | 325.00M | 368.50M | 364.40M | 344.30M | 311.10M |
| Gross Profit | 106.80M | 107.30M | 138.40M | 109.00M | 118.80M | 130.90M |
| EBITDA | 38.80M | 36.90M | 45.70M | 30.80M | 37.20M | 60.60M |
| Net Income | 25.20M | 22.60M | 24.40M | 15.40M | 24.90M | 44.60M |
Balance Sheet | ||||||
| Total Assets | 266.00M | 287.00M | 321.90M | 313.70M | 311.60M | 336.10M |
| Cash, Cash Equivalents and Short-Term Investments | 68.00M | 91.10M | 96.00M | 59.90M | 95.30M | 166.20M |
| Total Debt | 3.80M | 3.80M | 12.10M | 15.20M | 16.90M | 2.90M |
| Total Liabilities | 64.70M | 63.90M | 75.20M | 75.90M | 72.40M | 54.50M |
| Stockholders Equity | 201.30M | 223.10M | 246.70M | 237.80M | 239.20M | 281.60M |
Cash Flow | ||||||
| Free Cash Flow | 31.30M | 30.30M | 56.10M | -13.40M | 1.40M | 42.20M |
| Operating Cash Flow | 35.60M | 33.60M | 70.20M | -3.80M | 8.50M | 46.80M |
| Investing Cash Flow | -3.70M | 13.10M | -10.80M | -9.60M | -10.00M | -4.30M |
| Financing Cash Flow | -94.10M | -51.20M | -23.60M | -23.10M | -70.70M | -19.30M |
Fevertree Drinks Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:FEVR, the sentiment is Positive. The current price of 970.00 is above the 20-day moving average (MA) of 935.28, above the 50-day MA of 880.20, and above the 200-day MA of 835.88, indicating a bullish trend. The MACD of 21.37 indicates Negative momentum. The RSI at 65.12 is Neutral, neither overbought nor oversold. The STOCH value of 84.82 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:FEVR.
Fevertree Drinks Peers Comparison
Overall Rating
GB:NICL82.3Outperform
GB:CCH72Outperform
GB:BAG70Outperform
GB:FEVR64Neutral
GB:CDGP55Neutral
GB:CCR52Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 82Outperform | GBP 389.46M | 16.38 | 24.74% | 3.65% | 2.73% | 37.06% | |
| 72Outperform | GBP 15.85B | 18.89 | 25.10% | 2.35% | 12.76% | 12.70% | |
| 70Outperform | GBP 679.72M | 14.90 | 13.40% | 3.12% | 6.88% | -5.66% | |
| 64Neutral | GBP 1.06B | 44.97 | 11.88% | 1.80% | 1.74% | 2.83% | |
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| 55Neutral | GBP 82.54M | 234.21 | 0.97% | ― | 22.07% | ― | |
| 52Neutral | GBP 394.12M | 111.52 | 0.81% | 4.52% | -2.97% | -79.32% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:FEVR | Fevertree Drinks PLC | 970.00 | 212.72 | 28.09% | |
| GB:BAG | A G Barr | 611.00 | -8.36 | -1.35% | |
| GB:CCH | Coca Cola HBC | 4350.00 | 876.78 | 25.24% | |
| GB:NICL | Nichols plc | 1065.00 | 104.92 | 10.93% | |
| GB:CCR | C&C Group Plc | 107.00 | -14.81 | -12.16% | |
| GB:CDGP | Chapel Down Group plc | 44.50 | 6.50 | 17.11% |
Fevertree Drinks Corporate Events
Fever-Tree Director David Lapp Buys 23,800 Shares in Insider Deal
PositiveFever-Tree Drinks has disclosed that non-executive director David Lapp purchased 23,800 ordinary shares in the company on 20 October 2026 at an average price of £9.355 per share. The London Stock Exchange transaction, classified as a PDMR dealing, si...
Fever-Tree Launches Share Buyback and Plans Share Cancellation
PositiveFevertree Drinks plc has executed a series of share buybacks between 12 and 16 October 2026 on the London Stock Exchange’s main market and AIM, purchasing ordinary shares at volume‑weighted average prices ranging from about 877p to 916p. The transact...
Fever-Tree Launches Share Buyback and Plans Cancellation of Repurchased Stock
PositiveFevertree Drinks plc has undertaken a share buyback programme, purchasing a series of ordinary shares on the London Stock Exchange’s main market and AIM between 5 and 9 October 2026 through its broker Investec Bank. The transactions were executed at...
Fevertree Cancels Shares After Buyback on London Markets
PositiveFevertree Drinks has repurchased a series of ordinary shares on the London Stock Exchange’s main market and AIM between 28 September and 2 October 2026 under the authority granted at its 2025 AGM. The transactions, executed by Investec Bank, were car...
Fever-Tree Confirms Total Voting Rights Following Share Capital Update
NeutralFever-Tree has confirmed that its total issued share capital stands at 110,563,655 ordinary shares of 0.25p each, with one voting right attached to every share and no shares held in treasury. As a result, the total number of voting rights in the comp...
Fever-Tree Cancels Shares After Late-September Buyback
PositiveFevertree Drinks plc has executed a share buyback, purchasing a series of ordinary shares on the London Stock Exchange’s main market (XLON) and AIM (AIMX) between 21 and 25 September 2026. The trades were carried out via its broker Investec Bank, at...
Fever-Tree cancels newly repurchased shares in latest buyback
PositiveFevertree Drinks plc has repurchased a series of its own ordinary shares on U.K. venues, including the London Stock Exchange main market and AIM, between 14 and 18 September 2026. The buyback, executed via Investec Bank under previously granted share...
Fever-Tree Moves to Cancel Shares After Targeted Buyback
PositiveFever-Tree Drinks has moved to buy back its own shares, purchasing ordinary stock through Investec Bank between 7 and 11 September on the London Stock Exchange’s main market and AIM. The programme, executed under shareholder authority granted at the...
Fever-Tree chair boosts stake with share purchase on London market
PositiveFever-Tree, the premium mixers producer, reported that its non-executive chair, Domenic De Lorenzo, has increased his stake in the company through a share purchase on the London Stock Exchange. He acquired 44,674 ordinary shares at an average price o...
Fever-Tree Chair Increases Stake with Share Purchase
PositiveFever-Tree Drinks reported that its Non-Executive Chair, Domenic De Lorenzo, has acquired 44,674 ordinary shares in the company on the London Stock Exchange. The shares were purchased on 11 September 2026 at an average price of £7.7955, in a transact...
Fevertree lifts revenues and earnings as U.S. and U.K. growth gather pace
PositiveFevertree Drinks reported interim results for the six months to 30 June 2026 showing Fever-Tree brand revenue up 8% at constant currency to £183.6 million, with growth across all regions and record retail market share in ginger beer and tonic. The co...
Fever-Tree Moves to Cancel Shares After Early September Buyback
PositiveFevertree Drinks plc has repurchased a series of ordinary shares on both the London Stock Exchange and AIM between 1 September and 4 September 2026 under authority granted at its 2025 AGM. The trades, executed via broker Investec Bank, were carried o...
Fever-Tree Cancels Shares After Late-August Buyback Spree
PositiveFevertree Drinks has launched a share buyback programme, purchasing tens of thousands of ordinary shares on the London Stock Exchange and AIM between 24 and 28 August 2026 at volume-weighted average prices around 851–860 pence. The company has stated...
Fever-Tree Clarifies Total Voting Rights and Share Capital Structure
NeutralFever-Tree Drinks has confirmed that its total issued share capital comprises 111,504,742 ordinary shares, each carrying one voting right, and that it holds no shares in treasury. The declaration sets the official total number of voting rights at 111...
Fevertree Drinks to Cancel Shares After August Buyback Programme
PositiveFevertree Drinks plc has initiated a share buyback programme, purchasing a series of ordinary shares on the London Stock Exchange and AIM between 17 August and 21 August 2026 through its broker Investec Bank. The transactions were executed under shar...
Fever-Tree Launches Share Buyback and Plans Cancellation of Repurchased Stock
PositiveFevertree Drinks plc has repurchased a series of ordinary shares between 10 and 14 August 2026 on the London Stock Exchange’s main market and AIM, acting under a previously approved shareholder authority. The trades, executed via Investec Bank, were...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026
